SCM
INMB icon

Sterling Capital Management’s INmune Bio INMB Stock Holding History

Sterling Capital Management’s Portfolio INMB Stock Details INMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-136
Closed -$154 – 3348
2026
Q1 		$154 Hold
136
– – ﹤0.01% 3194
2025
Q4 		$212 Buy
136
+85
+167% +$152 ﹤0.01% 3219
2025
Q3 		$106 Buy
51
+19
+59% +$43 ﹤0.01% 3233
2025
Q2 		$74 Buy
32
+19
+146% +$139 ﹤0.01% 3254
2025
Q1 		$102 Hold
13
– – ﹤0.01% 3144
2024
Q4 		$61 Hold
13
– – ﹤0.01% 3202
2024
Q3 		$70 Buy
+13
New +$92 ﹤0.01% 3221

Other funds holding INMB

CWP
Curated Wealth Partners El Segundo, California $774M AUM 5.71% 1-Year Est. Return
WIM
Westside Investment Management Santa Monica, California $761M AUM 39.85% 1-Year Est. Return
AHL
Abel Hall LLC Baton Rouge, Louisiana $579M AUM 54.21% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
DC
Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return
LSA
Leonteq Securities AG Zurich, Switzerland $2.91B AUM 56.5% 1-Year Est. Return
EWA
EverSource Wealth Advisors Birmingham, Alabama $2.97B AUM 28.74% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

Sterling Capital Management's INMB Position: Q2 2026 in Review

Sterling Capital Management sold out of INmune Bio (INMB) in Q2 2026, closing a stake of 136 shares — an estimated $154 sold.

Sterling Capital Management first reported a position in INMB in Q3 2024 and held it in 7 quarters. The position peaked at $212 in Q4 2025. 16 funds tracked by Wall St. Rank hold INMB as of Q2 2026.

  • Sterling Capital Management reported no remaining INmune Bio position as of Q2 2026 after selling out during the quarter.
  • Sterling Capital Management sold 136 INmune Bio shares in Q2 2026, an estimated $154.
  • Sterling Capital Management first reported a position in INmune Bio in Q3 2024 and held it in 7 quarters.
  • Sterling Capital Management's INmune Bio position peaked at $212 in Q4 2025.
  • 16 funds tracked by Wall St. Rank held INmune Bio as of Q2 2026.

Based on Sterling Capital Management's 13F filing for Q2 2026, filed 28 Jul 2026.